Agilysys director Michael Kaufman sells common shares worth ~$8.15M
Agilysys (NASDAQ:AGYS) disclosed on Thursday that director Michael Kaufman sold ~95.8K common shares at an average price of...
Month: November 2023
British American Tobacco Vs. Altria: Which Is The Better Dividend Choice?
Summary: Comparing British American Tobacco and Altria reveals no clear winner; the most suitable choice depends on the...
Medtronic: On The Verge Of A Massive Turnaround
Summary: Medtronic's recent earnings report has boosted investor confidence, suggesting the worst may be over for the...
AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology
Summary: AbbVie is set to acquire ImmunoGen for $10.1 billion, gaining Elahere, a promising ovarian cancer treatment, and...
Affimed slips as finance chief and science chief depart
pcess609 Affimed N.V. (NASDAQ:AFMD) shares lost ~13% on Thursday after the German biotech announced that its Chief...
3M: Time To Load Up On This 6.1% Yield
Summary: 3M's stock has faced significant pressure since 2020 following the Earplug Lawsuit, erasing all gains made in the...
Not A Bubble! Julian Lin On Tech’s Profitability And Reasonable Valuations
Summary: Tech stock valuations are becoming less compelling, but not in bubble territory.Julian Lin is shifting focus to...
Johnson & Johnson: Sleep Well At Night With The Only AAA-Rated Dividend Aristocrat
Summary: As a Dividend King with six decades of dividend growth to its credit and a AAA credit rating from S&P, Johnson...
AbbVie’s $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained
Summary: AbbVie Inc. is set to acquire drug developer ImmunoGen, Inc. for $10.1 billion, diversifying its oncology pipeline...
3M: Stock Stabilizing, Remains Undervalued With Strong Free Cash Flow
Summary: 3M has a string of decent quarterly earnings beats and stock price reactions.With a historically high free cash...